{"name":"Athira Pharma","slug":"athira","ticker":"ATHA","exchange":"NASDAQ","domain":"athira.com","description":"Athira Pharma is a late clinical stage American biopharmaceutical company developing small-molecule therapeutics targeting neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. The company's lead candidate, ATH-1017, is in human studies for Alzheimer's disease as of 2021.","hq":"Bothell, WA","founded":0,"employees":"","ceo":"Mark Litton, Ph.D.","sector":"Neuroscience / Clinical-Stage Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$120M","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":17500000,"netIncome":-105609000,"cash":69276000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"ATH-1017 patent cliff ($0.00 at risk)","drug":"ATH-1017","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"ATH-1020 patent cliff ($0.00 at risk)","drug":"ATH-1020","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Athira Pharma Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Athira Pharma reported its fourth quarter and full year 2023 financial results, with a net loss of $44.8 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Athira Pharma Announces $50 Million Private Placement Financing","summary":"Athira Pharma announced a $50 million private placement financing, which will be used to support the company's clinical development programs.","drugName":"","sentiment":"positive"},{"date":"2023-08-14","type":"trial","headline":"Athira Pharma Announces Positive Topline Results from Phase 2 Clinical Trial of ATH-1017","summary":"Athira Pharma announced positive topline results from its Phase 2 clinical trial of ATH-1017, which is being developed for the treatment of Alzheimer's disease.","drugName":"ATH-1017","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiS0FVX3lxTE1rUl8za0dtbkozb1JTZW9uTExnNFZMNlpYVlV1M1M1QThCazAxVDBtSEs0b3BVaGE2c1c3aE5wTi1OOEFqSklScmVnMA?oc=5","date":"2026-04-02","type":"pipeline","source":"meyka.com","summary":"Athira Pharma, Inc. (ATHA) Competitors - meyka.com","headline":"Athira Pharma, Inc. (ATHA) Competitors","sentiment":"neutral"},{"date":"2026-03-31","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-19","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNSXlqYmRiRWFnNGxkbXVOc2hNUmtKTTI5cmhBQm1EbnRWRTNLbV9rUktWZXFHWU1PQ2Z6Qmd6a0c0Y2lXaWVEek83SGRfSzZnS1FqTUk3MnRGQ1ZzQWZKSkxXQzQtc245YXZXVmROanN5WFFoS1J5MWdEMksyZFlKcmNSRnphMTRH?oc=5","date":"2026-01-09","type":"pipeline","source":"Yahoo Finance","summary":"Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA” - Yahoo Finance","headline":"Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA”","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiyAFBVV95cUxNT21ob0o4YzRBWFMxbVJUM3B4NXQ5eGRzUXhOaHZsOHBJSnVMLWhKUFRJaVVmeVh1UE9OYS11TDJOTmxyWV84Q1cxS1dyT1JzSVdCRmNEdnJGRUV5UWpVWTdLc0Y5aGNWdGtLYjBUeFF3UzNpeldsR3N4QkdOS0dObV8xZl9pS2lUX09aODNWazBpbVU2bUFuZVNPU2xHX09SS0ZQRXFRNGw0Y0w1UHN6bkpKSHluek9aMklrRzFGSzBRcTV1R3N5eg?oc=5","date":"2026-01-05","type":"pipeline","source":"Investing.com","summary":"Worthington, Athira Pharma general counsel, sells $6k in ATHA stock - Investing.com","headline":"Worthington, Athira Pharma general counsel, sells $6k in ATHA stock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOTHFsdWRxbWd1NVJyWEIwR3U5WjBUZkhWZW1jeVZmLTBIMHEweUx5VWQ1dnlSWVE3OTgtRTNPWks4ZmVUdS1XSy1UVWR3c0Y4ekx0MDZMcmlpVERDT0VGTXFGZF93WW9FVEpPbVFzcW1Ib1V1RHMwUUNEbDlnWTZzSms0UFpIcDlpSVBPRHN0TE95Q0REdjNHUDRmZnhQMk1pM2RscTZKREstUkdFMzRjWEtydmp6a3dJTGhQNUlB?oc=5","date":"2025-12-18","type":"pipeline","source":"GeekWire","summary":"Athira Pharma recovers from Alzheimer’s failure with breast cancer pivot and $90M investment - GeekWire","headline":"Athira Pharma recovers from Alzheimer’s failure with breast cancer pivot and $90M investment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgJBVV95cUxNVHVRUVM0SkhHZnZsRWN0TXdRZGZoQjJlUU0wMjkyREM0am9xWDFhd1pqZDdhSGZSNWNEeVNvVk5GQ080dzhSM0RnZngyaEVVNVFmaV9OUm16eEdmcHo0UmUwOXZ2LVdOVE5QVEwtVmFQLWQ5YXhHcWpHS25sZkxQeUZVYk5LaUhkM080TTRLN3lpcEhwejM5S2N2Y25kS1Q0bFlfZkVWRGNYTXpwMGlGaWxTaF92djd5bHNsbjAzeGpGRHg1amJNcV9lWnN1VWtxWFpuWHp2bkxRNmhGa3pxOVZ0OUY5OEpVN1dENlliSnY0QS14M3ZLbkhlWmFtRHJJdi02RlFVZXZ4c1N3UFE?oc=5","date":"2025-12-18","type":"trial","source":"Quiver Quantitative","summary":"Athira Pharma Enters License Agreement for Lasofoxifene Development, Secures $90 Million Financing for Phase 3 Trial in Metastatic Breast Cancer | ATHA Stock News - Quiver Quantitative","headline":"Athira Pharma Enters License Agreement for Lasofoxifene Development, Secures $90 Million Financing for Phase 3 Trial in ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTFBmdE5za1VGbWxVdjFMREVPVWlTc1Jtb3drSERXMEloZ2VlcTZnamttOWVLSXZ3RTNZMV81ZEp6R0RsSGRHT1RkVGg0QTdlYVVoa183Y2F0QnVLRWQydVpaVmlEZFhGdDBnZkNfZ3NQa1RWN3lmTVRwZkJB?oc=5","date":"2025-12-18","type":"pipeline","source":"TipRanks","summary":"Why Is Athira Pharma Stock (ATHA) Up Today? - TipRanks","headline":"Why Is Athira Pharma Stock (ATHA) Up Today?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxQUy1VbU5WOWxrZHlFb0htRWpIR1R6Y21MVFkxUmNNd0dtTFZCZlBCaUVPdXBnQzNHX21GR1ZLbXZkUWdKUE9NYWoyYnlyZWRfUktTOVdqNFVqTFRlMDBUdURwd3pHci1YQlVDREJDWURBNDM1X2toVDdLSjU0UDhiTW42RzRITE5LOGhGZGFuVXZHMnUtajFDV1lrLXlDNVdacmw2LXhDY3VrekNCbC1yVFNCWkxDSGs0ZURIRHRpNDdTSV9yU0pibnlhaTdjSm1GVkc3NGhmQQ?oc=5","date":"2025-12-18","type":"trial","source":"Investing.com","summary":"Athira Pharma stock soars after acquiring rights to Phase 3 breast cancer drug - Investing.com","headline":"Athira Pharma stock soars after acquiring rights to Phase 3 breast cancer drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizwFBVV95cUxPeHR6Q0VTZFd4UHFyYmwzQWt1QlZ4dWZFQWFlUDlHakxZc2FJLWRGSFVITXNpMDh1ZExDbU5fSWlwVFI3cjB4d2hUN2FPUG0xTFBLUi1QdG9DMV9zcjJFYzhlWXdodnZEei05RElheW1JVkdQekt6c2xSSUt0bTI1QTZqc2ZQS1BONjZoYWVTZzhCLVF3YjJsNnoyOXF5ZXpnRE5Sb3M5M3B6TTlmeUNuR2I4cUdFVHQ3NFpGVDNoQ3FFNmh3Z0Z4dGR1WFI3dU0?oc=5","date":"2025-12-18","type":"pipeline","source":"Stocktwits","summary":"Athira Pharma Stock Shot Up 60% Today – What’s Triggering The Super Rally? - Stocktwits","headline":"Athira Pharma Stock Shot Up 60% Today – What’s Triggering The Super Rally?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE43alVlckNXMF84RjZKTjZUekpKY285S3BkRmFRNmNxQnpDRXFnRFlpVk5sZ3RoSXIxWi14VEtMSHBmMVRPdklkLUVNVGVmLWMxWGhVR2x4aTNfSHRxejJCMGFtOWRJR1BYanBEeHNQanNMc2FYMFpTM3JR?oc=5","date":"2025-12-18","type":"pipeline","source":"StocksToTrade","summary":"Athira Pharma Inc.: Growth or Bubble? - StocksToTrade","headline":"Athira Pharma Inc.: Growth or Bubble?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNWkZlNU9vS0Y4aklkaU5XVHk4dm5BZF9GZjZ5V3hrN19VZDJoUUQyWXBReEdnV1ZLMElUS2VXS09XSTcyaXlKX3lfcTJnNV9kRmU4eVlIM1pEZ0c4SldLXzJkczlBa1Y1akdBYzU0NDU2eVFTUTc1WEd6Q3RYOThsS1YzNjRSZlE3OUdWcWdLaUd1ZkpkV1lEVkRhTnI?oc=5","date":"2025-12-18","type":"pipeline","source":"The Business Journals","summary":"Athira Pharma raises $90 million as Bothell firm shifts focus - The Business Journals","headline":"Athira Pharma raises $90 million as Bothell firm shifts focus","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxNemR4YmtQM0lBWUNTbFRhY1VIVmYwZ0NPTWdRck1DajZpMTltSl9lTUVOU3J3NkhOcWNUNmpiN1BEa0lHbGwzRG1oVi1pZ05ab1RoSDZ5ZW56TnpXcG9FMUVMU0NBN1VjNnkzVGxDVURDZGZRSFZQSGptNVprdjB6bVprbXJ4MHdUc1Vr?oc=5","date":"2025-09-11","type":"pipeline","source":"Yahoo Finance","summary":"Athira Pharma Announces Reverse Stock Split - Yahoo Finance","headline":"Athira Pharma Announces Reverse Stock Split","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPa2ZJTlRkTHZoOEk5Q0t5UkxnTmNwSGlIRlpqNHZSZlVJb2JmYXRESEQwMG5yQkxmVzhyX3FXX3J2YkFjbkowelU2V2RLUWdEWGRRRmJrQ01WVmZKblI5VHRtUFdoUVZsYVdPTVZLSTAwUjZZU0dGWTZwWHU2R204M2hjREVHMk14WTE4djVoUE1rY3NsS1UwaGJhREdmQ1kyeWIzZ2VRSUQ2bVVHMUpacg?oc=5","date":"2025-07-02","type":"pipeline","source":"Stock Titan","summary":"[Form 4] Athira Pharma, Inc. Insider Trading Activity - Stock Titan","headline":"[Form 4] Athira Pharma, Inc. Insider Trading Activity","sentiment":"neutral"}],"patents":[{"drugName":"ATH-1017","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0},{"drugName":"ATH-1020","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US","annualRevenue":0}],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Biogen","Eli Lilly","Roche"],"therapeuticFocus":["Alzheimer's disease","Neurodegenerative disorders"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":17500000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-105609000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":69276000,"cashHistory":[],"totalAssets":92151000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}